Dr. Plimack provides a brief overview of the prevalence of non-clear cell renal cell carcinoma and a short description of their subtypes.
The Evolving Landscape of Non-Clear Cell Renal Cell Carcinoma
An expert discusses key data points from the KEYNOTE B61 extended follow up of Lenvatinib plus pembrolizumab in first line setting in non-clear cell renal cell carcinoma.
Elizabeth Plimack, MD discusses recent results from the phase 2 nivolumab and cabozantinib trial in nccRCC.
Dr. Plimack shares her insights on some unmeet needs and challenges when treating non-clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
